Fate Therapeutics Announces FDA Fast Track Designation for ProTmune™
June 20, 2016 08:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, June 20, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...